Hypertrophy

Cor.At® pure cardiomyocytes provide a unique cellular model for hypertrophic cardiomyopathy that makes the drug discovery and development process more efficient and convenient. See also our My.Cor service.

Cor.At® stem cell-derived mouse cardiomyocytes are reliably induced to reproduce features of hypertrophic cardiomyocytes when stimulated with specific agonists.

They allow the determination of a compounds effect on hypertrophic cardiomyocytesin vitro and enable screening of large compound libraries. This system has been validated with reference drugs known to suppress cardiomyopathy (Fig.1).

Initial proof-of-concept studies have also shown that use of Cor.4U@ human iPS cell-derived cardiomyocytes work extremely well within the My.Cor system.  This comes as pharmaceutical companies continue to seek more translational in vitro models of human disease. See also our My.Cor service.

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10